title: Hematopoietic stem cell transplantation for adults with acute promyelocytic leukemia in the ATRA era: a survey of the European Cooperative Group for Blood and Marrow Transplantation.
abstract: We performed a survey of the European Cooperative Group for Blood and Marrow Transplantation to analyze the outcome of 625 acute promyelocytic leukemia (APL) patients transplanted with auto- or allogeneic-hematopoietic stem cell transplantation (autoHSCT, alloHSCT) after 1993, in first (CR1) or in second complete remission (CR2). Leukemia-free survival (LFS) at 5 years in CR1 was 69% for 149 patients autografted and 68% for 144 patients allografted, whereas in CR2, LFS was 51% in 195 autoHSCT and 59% in 137 alloHSCT recipients, respectively. In the group of autoHSCT for CR1 (n=149), higher relapse incidence (RI) was associated with shorter time from diagnosis to transplant (<7.6 months); transplant-related mortality (TRM) was increased in older patients (>47 years), whereas for CR2, longer time from diagnosis to transplant (>18 months) was associated with increased LFS and decreased RI. In the alloHSCT group for CR1 (n=144), age (<33 years) was associated with increased LFS and decreased TRM and for CR2 (n=137), the use of mobilized peripheral blood stem cells was associated with decreased TRM. Female recipient, a female donor to male recipient and transplants performed before 1997 were associated with decreased RI. In conclusion, HSCT still appears to have a role in APL, especially for patients in CR2.
authors.affiliation: Hematology Service, Hospital Universitario La Fe, Valencia, Spain. msanz@uv.es
authors.forename: M A
authors.initials: MA
authors.lastname: Sanz
authors.forename: M
authors.initials: M
authors.lastname: Labopin
authors.forename: N-C
authors.initials: NC
authors.lastname: Gorin
authors.forename: J
authors.initials: J
authors.lastname: de la Rubia
authors.forename: W
authors.initials: W
authors.lastname: Arcese
authors.forename: G
authors.initials: G
authors.lastname: Meloni
authors.forename: A
authors.initials: A
authors.lastname: Bacigalupo
authors.forename: P
authors.initials: P
authors.lastname: Alessandrino
authors.forename: E
authors.initials: E
authors.lastname: Carreras
authors.forename: A
authors.initials: A
authors.lastname: Iriondo
authors.forename: N
authors.initials: N
authors.lastname: Novitzky
authors.forename: P
authors.initials: P
authors.lastname: Jacobs
authors.forename: G
authors.initials: G
authors.lastname: Bandini
authors.forename: F
authors.initials: F
authors.lastname: Lo-Coco
authors.forename: F
authors.initials: F
authors.lastname: Frassoni
authors.forename: V
authors.initials: V
authors.lastname: Rocha
mesh_terms: D000293:Adolescent; D000328:Adult; D000818:Animals; D018572:Disease-Free Survival; D005260:Female; D005500:Follow-Up Studies; D006306:Health Surveys; D018380:Hematopoietic Stem Cell Transplantation / Q000706:statistics & numerical data; D006801:Humans; D015473:Leukemia, Promyelocytic, Acute / Q000401:mortality / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D012008:Recurrence; D012189:Retrospective Studies; D016019:Survival Analysis; D013997:Time Factors; D014182:Transplantation, Autologous; D014184:Transplantation, Homologous; D016896:Treatment Outcome